GB2596001B - Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class I-like protein (OMCP) and tumor-specific binding partner - Google Patents

Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class I-like protein (OMCP) and tumor-specific binding partner Download PDF

Info

Publication number
GB2596001B
GB2596001B GB2112934.1A GB202112934A GB2596001B GB 2596001 B GB2596001 B GB 2596001B GB 202112934 A GB202112934 A GB 202112934A GB 2596001 B GB2596001 B GB 2596001B
Authority
GB
United Kingdom
Prior art keywords
protein
omcp
mhc
tumor
class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2112934.1A
Other languages
English (en)
Other versions
GB202112934D0 (en
GB2596001A (en
GB2596001A8 (en
Inventor
Sasha Krupnick Alexander
Reed Lazear Eric
Hein Sarah
Marvin Watkins Daniel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Courier Therapeutics Inc
Courier Therapeutics Inc
Original Assignee
Courier Therapeutics Inc
Courier Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Courier Therapeutics Inc, Courier Therapeutics Inc filed Critical Courier Therapeutics Inc
Publication of GB202112934D0 publication Critical patent/GB202112934D0/en
Publication of GB2596001A publication Critical patent/GB2596001A/en
Publication of GB2596001A8 publication Critical patent/GB2596001A8/en
Application granted granted Critical
Publication of GB2596001B publication Critical patent/GB2596001B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB2112934.1A 2019-02-18 2020-02-18 Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class I-like protein (OMCP) and tumor-specific binding partner Active GB2596001B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962807190P 2019-02-18 2019-02-18
PCT/US2020/018680 WO2020172189A1 (en) 2019-02-18 2020-02-18 BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER

Publications (4)

Publication Number Publication Date
GB202112934D0 GB202112934D0 (en) 2021-10-27
GB2596001A GB2596001A (en) 2021-12-15
GB2596001A8 GB2596001A8 (en) 2022-08-24
GB2596001B true GB2596001B (en) 2023-11-29

Family

ID=72144178

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2112934.1A Active GB2596001B (en) 2019-02-18 2020-02-18 Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class I-like protein (OMCP) and tumor-specific binding partner

Country Status (11)

Country Link
US (2) US20230002450A1 (cg-RX-API-DMAC10.html)
EP (1) EP3927722A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022520978A (cg-RX-API-DMAC10.html)
KR (1) KR20210131373A (cg-RX-API-DMAC10.html)
CN (1) CN114072416A (cg-RX-API-DMAC10.html)
AU (1) AU2020226493B2 (cg-RX-API-DMAC10.html)
CA (1) CA3130582A1 (cg-RX-API-DMAC10.html)
GB (1) GB2596001B (cg-RX-API-DMAC10.html)
IL (1) IL285668A (cg-RX-API-DMAC10.html)
SG (1) SG11202108878VA (cg-RX-API-DMAC10.html)
WO (1) WO2020172189A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
JP2021523140A (ja) * 2018-05-07 2021-09-02 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16、及び腫瘍関連抗原に結合するタンパク質
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
JP2024529381A (ja) * 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001071005A2 (en) * 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
WO2007002905A1 (en) * 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
WO2017024131A1 (en) * 2015-08-04 2017-02-09 Avidbiotics Corp. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors
WO2017136818A2 (en) * 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
WO2017143406A1 (en) * 2016-02-26 2017-08-31 Imunexus Pty Ltd Multi-specific molecules
CN107226866A (zh) * 2017-07-05 2017-10-03 中国药科大学 一种抗cd24人源化抗体融合蛋白
US20180030111A1 (en) * 2015-05-07 2018-02-01 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Fc mutants with modified functional activity
US20180201689A1 (en) * 2015-08-18 2018-07-19 Institute Of Microbiology, Chinese Academy Of Sciences Antibody Fusion Protein and Preparation Method and Use Thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
US20120294857A1 (en) * 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
LT3227311T (lt) * 2014-12-05 2022-02-25 Xyphos Biosciences Inc. Įterpiami variabilūs antikūnų fragmentai ir nkg2d ligandų modifikuoti a1-a2 domenai
WO2016100375A2 (en) * 2014-12-15 2016-06-23 Washington University Compositions and methods for targeted cytokine delivery
CN107530424A (zh) * 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
EP3475300A2 (en) * 2016-06-24 2019-05-01 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
CN110944651A (zh) * 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001071005A2 (en) * 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
WO2007002905A1 (en) * 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
US20180030111A1 (en) * 2015-05-07 2018-02-01 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Fc mutants with modified functional activity
WO2017024131A1 (en) * 2015-08-04 2017-02-09 Avidbiotics Corp. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors
US20180201689A1 (en) * 2015-08-18 2018-07-19 Institute Of Microbiology, Chinese Academy Of Sciences Antibody Fusion Protein and Preparation Method and Use Thereof
WO2017136818A2 (en) * 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
WO2017143406A1 (en) * 2016-02-26 2017-08-31 Imunexus Pty Ltd Multi-specific molecules
CN107226866A (zh) * 2017-07-05 2017-10-03 中国药科大学 一种抗cd24人源化抗体融合蛋白

Also Published As

Publication number Publication date
AU2020226493B2 (en) 2025-10-23
EP3927722A4 (en) 2022-11-23
WO2020172189A1 (en) 2020-08-27
GB202112934D0 (en) 2021-10-27
CA3130582A1 (en) 2020-08-27
CN114072416A (zh) 2022-02-18
US20260008822A1 (en) 2026-01-08
EP3927722A1 (en) 2021-12-29
IL285668A (en) 2021-10-31
US20230002450A1 (en) 2023-01-05
SG11202108878VA (en) 2021-09-29
JP2022520978A (ja) 2022-04-04
KR20210131373A (ko) 2021-11-02
GB2596001A (en) 2021-12-15
GB2596001A8 (en) 2022-08-24
AU2020226493A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
GB202112934D0 (en) Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class 1-like protein (OMCP) and tumor-specific binding partner
IL280673A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
DK3833386T5 (da) Multispecifikke bindende proteiner, der binder her2, nkg2d og cd16, og anvendelsesmetoder
IL281323A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
IL288597A (en) Fusion of cea-binding antibody and 4-1bbl
IL281305A (en) Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1
IL270803A (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
IL272706A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
MX2024000742A (es) Anticuerpos anti-tigit.
IL270801A (en) NKG2D, CD16 and tumor-associated antigen binding protein
EP4025602A4 (en) TSLP BINDING ANTIBODIES AND USES THEREOF
DK3582806T3 (da) Proteiner, der binder her2, nkg2d og cd16
EP3847196A4 (en) BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
SG11202101298XA (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
CL2018002034A1 (es) Proteínas de unión a antígeno que se unen a pd-l1.
SG11202009804RA (en) Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
EP3583131A4 (en) PROTEINS THAT BIND CD33, NKG2D AND CD16
EP3579878A4 (en) PROTEINS BINDING PSMA, NKG2D AND CD16
SG11202000632QA (en) Proteins binding nkg2d, cd16 and flt3
EP3689893A4 (en) IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE
UY36731A (es) Proteinas de unión contra vegf, pdgf, y/o sus receptores
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
EP4308604A4 (en) PD-L1-BINDING ANTIBODIES AND USES THEREOF
HK40068565B (en) Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class 1-like protein (omcp) and tumor-specific binding partner
HK40055054A (en) Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068565

Country of ref document: HK

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20241017 AND 20241023